News Hub | News Direct

Communications

Advertising Communications Graphic Design Internet Marketing Media Publishing SEO
Article thumbnail News Release

Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit

Silexion Therapeutics Corp

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced its participation in the 2024 Maxim Healthcare Virtual Summit, scheduled to take place from October 15 to 17, 2024. Ilan Hadar, Chief Executive Officer and Dr. Mitchell Shirvan, Chief Scientific and Development Officer will join a fireside chat hosted by Jason McCarthy, Senior Managing Director and Head of Biotechnology Research at Maxim Group, on Thursday, October 17, 2024, at 9:30am ET. The event will be streamed live on M-Vest and accessible to members by clicking here or via following link: https://m-vest.com/events/healthcare-10152024. The Company’s management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact their Maxim representative to schedule a meeting. About Silexion Therapeutics: Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com Contact Details Silexion Therapeutics Corp Ms. Mirit Horenshtein Hadar, CFO mirit@silexion.com ARX | Capital Markets Advisors North American Equities Desk silexion@arxadvisory.com

October 09, 2024 04:30 PM Eastern Daylight Time

Article thumbnail News Release

Kevel partners with the World’s Largest Home Improvement Retailer to in-house its retail media technology for Orange Apron Media

Kevel

Both Kevel and Orange Apron Media share a common goal: advertising partner success. They understand that having a tangible impact on their partners’ businesses and success transcends traditional revenue goals and emphasizes a symbiotic relationship where growth is intrinsically tied to the prosperity of their clients. While the partnership between Kevel and Orange Apron Media has just officially launched, it promises to continue to bring innovation to the retail media landscape. Kevel, the API-first ad serving company, is formally announcing its partnership with The Home Depot to support its in-house transformation of its retail media network’s, Orange Apron Media Technology. After six years of providing home improvement retail media solutions, Orange Apron Media embarked on a new journey of transformation and innovation. The Orange Apron Media team will rely on Kevel's Retail Media Cloud™ to power its in-house journey as the company continues to transform and innovate its services. As the home improvement retailer looked to lean further into their competitive edge as a specialty retailer, continuing to innovate their retail media offerings and capabilities for advertisers, they knew flexibility and innovation would be vital. Orange Apron Media turned to Kevel’s flexible, API-based Retail Media Cloud TM solution to power its in-house retail media technology. With the addition of Kevel’s Retail Media Cloud TM, Orange Apron Media built a differentiated retail media network and added value to its ad products by enabling advertisers to connect with customers closer to the point of purchase. Working closely with the Kevel team to upgrade its in-house retail media technology, the Orange Apron Media team will continue to double down on its goal to provide advertisers with value and performance. Through this collaboration Orange Apron Media and Kevel will continue to seamlessly integrate retail media offerings into its digital strategies, emphasizing enhancements to the customer experience across both owned and off-site channels through storytelling and personalization leveraging unique first-party data. “Providing the best possible service and experience for our customers and our advertising partners is at the top of our list of priorities,” said Melanie Babcock, vice president of Orange Apron Media and Monetization. “Finding like-minded partners, like Kevel, makes it easier to build custom solutions that help brands connect with customers at the right place and at the right time. When customization is done right, it enhances everyone’s experience.” Both Kevel and Orange Apron Media are dedicated to enhancing their solutions through innovation and continue to stay at the forefront of the constantly evolving digital advertising landscape, making the partnership an excellent fit at a pivotal time in the industry. Kevel continues to stand out amongst ad tech solution providers as the only API-based solution for in-housing retail media technology, allowing retailers to differentiate based on their unique brand and first-party data. Orange Apron Media is forging the path for specialty retailers by developing an enhanced omnichannel customer experience through ads that tell a story across the customer journey, ensuring their advertisers receive at least two-times return on their ad spend. “There has been a large shift in the retail media landscape as brands focus on the retail media networks that deliver real value versus those that are commoditized and not fit for purpose. This is pushing retailers to move from off the shelf solutions to build high-end, differentiated retail media networks,” says James Avery, Founder & CEO Kevel. “Kevel’s flexible API-based Retail Media Cloud was designed specifically to enable retailers like Orange Apron to build customized in-house retail media solutions in a way that really differentiates them, leveraging their unique attributes to provide advertisers with innovative, cutting edge decisioning, ad formats, targeting, and site performance, all while keeping their data safe and secure at scale.” About Kevel Kevel is powering innovative, flexible ad tech infrastructure APIs that fuel its Retail Media Cloud™. This unique offering is the only API-based solution for in-housing retail media technology that enables multi-brand retailers to differentiate based on their unique brand, improving shopper experience while maintaining total control of their first-party data.Kevel believes that every digital retailer should have the capability to build and scale their own distinct ad platform, just like big tech players like Amazon. Customers like Edmunds, Delivery Hero, Sonae, Leroy Merlin, Slickdeals, and other leading retailers and marketplaces all launched their own retail media networks with Kevel.The company has garnered numerous accolades, most recently earning recognition as one of the leading 100 innovative tech start-ups driving the future of brand-to-consumer in 2023 and awarded the MarTech Breakthrough Award for best overall ad tech company in 2022. Learn more at www.kevel.com About Orange Apron Media The Home Depot Retail Media network offers businesses like yours the opportunity to connect with consumers like never before. Regardless of your budget, we have a solution to meet your marketing needs. Choose one of our advertising offerings or mix and match to find what is right for your company and your specific products. The Home Depot advertising department leverages a myriad of online and offline channels to spread awareness of your brand and promote your products. From email advertising to social media branded marketing, these solutions are designed to propel your business and help increase sales. The Home Depot's advertising center tracks customer interest via our website, enabling us to promote your brand through retargeted ads and other off-site channels to keep your products top of mind. Retail advertising is key to setting yourself apart from competitors in an ever-changing market. About The Home Depot The Home Depot is the world's largest home improvement specialty retailer. At the end of the first quarter, the company operated a total of 2,324 retail stores in all 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, Guam, 10 Canadian provinces and Mexico. The company employs approximately 475,000 associates. The Home Depot's stock is traded on the New York Stock Exchange (NYSE: HD) and is included in the Dow Jones industrial average and Standard & Poor's 500 index. The Home Depot is #17 on the 2022 Fortune 500. Contact Details Kevel Jennifer Choo, Director of Marketing +1 973-343-8819 jchoo@kevel.com

October 08, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

NAVEX Unveils Curated AI Content Library to Simplify Compliance and Risk Mitigation

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management software, introduces its new AI-focused content library designed to help organizations address the rapidly evolving landscape of Artificial Intelligence (AI) regulations and frameworks. As AI technologies become part of daily operations, many organizations find themselves entering uncharted waters regarding effective AI governance. According to Forrester’s September 2023 Artificial Intelligence Pulse Survey, 56% of AI decision-makers said their organization will use generative AI (genAI) in the next 12 months for internal or customer-facing production applications for employee productivity. The stakes are rising, and navigating these challenges without a clear framework can feel overwhelming, leaving companies vulnerable to risks. NAVEX plays a critical role by enabling companies to implement strong controls, automate workflows, and perform comprehensive testing. This approach simplifies complex challenges and transforms them into strategic opportunities. NAVEX’s content library is continuously curated to cover international and industry-specific AI regulations, including emerging standards and compliance requirements. By leveraging this resource, customers can ensure their AI initiatives align with ethical guidelines and regulatory mandates. A.G. Lambert, Chief Product Officer at NAVEX, captures the pivotal moment many organizations face: "As AI technologies revolutionize industries, companies find themselves standing at a crossroads, navigating the intricate landscape of effective AI governance. Our AI content not only empowers risk management professionals to establish crucial controls but also enhances efficiency by automating compliance processes. This dual approach enables organizations to embrace AI technology with confidence, transforming challenges into opportunities for growth and innovation." Key features of the NAVEX AI content library include: Centralized AI Regulatory Resources: Access a consolidated library of global AI regulations and industry-specific guidelines. Streamlined Control Development: Simplify the process of creating and implementing AI-specific controls to align with emerging regulations. Automated Compliance Monitoring: Leverage automation to track compliance requirements and ensure adherence through continuous control testing. Enhanced Risk Mitigation: Identify and mitigate AI-related risks proactively using structured regulatory frameworks. Future-Proof Compliance Strategy: Stay ahead of evolving AI laws and standards, ensuring the organization remains compliant and competitive. NAVEX is enhancing AI governance with its NAVEX One platform that streamlines the process of developing and distributing AI-related policies, ensuring companies stay aligned with fast-changing compliance requirements in the AI landscape. Should employees or third parties have AI-related issues or concerns, the NAVEX One platform offers employees a secure solution to report them. This proactive approach helps organizations identify and mitigate potential risks early on. The NAVEX content library offers over 400 regulations and compliance frameworks, continuously expanding to meet the demands of an evolving regulatory environment. This extensive resource includes critical AI regulations such as the EU AI Act, NIST AI Risk Management Framework, and the Colorado Artificial Intelligence Act. As AI governance becomes increasingly critical, NAVEX integrates AI training, incident management, and policy management into this comprehensive resource, ensuring organizations stay ahead of compliance requirements. With real-time updates, businesses can select tailored content to meet emerging AI regulatory standards, providing the tools to navigate current and future compliance challenges effectively. This seamless integration helps organizations maintain a proactive risk and compliance posture while leveraging cutting-edge technologies. The new AI content library is now available as part of NAVEX’s Integrated Risk Management solution. For more information, visit NAVEX’s Website. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

October 08, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

Market Alert: Silexion Therapeutics (NASDAQ: SLXN) Sees Record Volumes Following Breakthrough Preclinical Data for SIL-204

Global Markets News

Shares of Silexion Therapeutics (NASDAQ:SLXN) are seeing significatnly today after the company announced promising new preclinical data for its next-generation siRNA candidate, SIL-204. The stock saw a significant initial of price spike of over 50% in pre-market activity as investors responded to the latest developments in Silexion's RNA interference (RNAi) platform, which targets KRAS-driven cancers. As of now, volume is at record highs, currently standing at over 50 million shares today. The company revealed that SIL-204, an extended-release microparticle formulation, demonstrated substantial tumor reduction and necrosis in mouse models of pancreatic cancer bearing the KRAS G12D mutation—one of the most common mutations found in pancreatic cancer patients. This latest data builds on a string of recent successes for Silexion, including its September 24 announcement of results from the Phase 2 trial for its first-generation product, LODER™, which showed significant improvements in tumor resectability among non-resectable pancreatic cancer patients. Alongside the new preclinical results, Silexion has recently reported plans to begin toxicology studies for SIL-204 in preparation for Phase 2/3 clinical trials expected to commence in the first half of 2026. The company is also expanding the application of its siRNA technology to colorectal cancer models, reflecting its broader ambitions to target multiple KRAS-driven cancers, which are notoriously difficult to treat with conventional therapies. While stock price has pulled back since premarket, The spike in Silexion’s market activity as marked by these record high volumes (according to market data) may highlight the growing market interest in the company’s novel approach to tackling cancers with high unmet medical needs, particularly its focus on KRAS mutations, which are common across a variety of aggressive cancers, including pancreatic and colorectal cancer. Silexion’s continued momentum in the precision oncology space potentially positions it as a leading player in the development of next-generation RNAi therapies. With its promising pipeline and recent positive developments, the company seems to be gaining attention as it advances toward clinical trials that could offer new hope for patients battling some of the deadliest cancers. Click here to read Silexion's full announcement *** This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/ab9dn/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

October 01, 2024 11:47 AM Eastern Daylight Time

Article thumbnail News Release

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

Article thumbnail News Release

VOESH New York Launches New 28 oz. Vegan Hand & Body Crème Collection

VOESH New York

VOESH New York is debuting a new 28 oz. Vegan Hand & Body Crème Collection, created to provide salon clients with a luxurious and healthier hydration experience. These larger bottles offer the same high-quality, vegan-friendly ingredients that have established VOESH as a leader in the body care industry. “We’re thrilled about the addition of these generously sized lotions to VOESH’s product line,” said Tom Harrison, Principal of Coleman Harrison. “VOESH consistently outshines the competition with expert formulas. This new size will undoubtedly enhance manicure and pedicure services, delivering superior results for both clients and technicians.” “As a bonus, technicians can pair these lotions with VOESH’s best-selling Pedi in a Box products,” added Kendall Stone, Principal of Jay Stone Sales. Enriched with 94+% natural-origin ingredients, VOESH’s 28 oz. crèmes are formulated with organic virgin olive oil and natural extracts. They are infused with 100% vegan, clean, and certified organic components and are free from parabens, phthalates, gluten, mineral oil, and more than 1,680 other potentially harmful substances. The velvety texture provides long-lasting moisture and a radiant glow without a greasy feel. These larger bottles not only provide a superior experience but also ensure lasting hydration and value. “Our lotions have always been a best-seller, so we’ve brought them back in a more convenient size for salons,” said Joseph Choi, Co-Founder of VOESH New York. “Salon owners have been asking for our popular massage butter in a bottle, and we’re ecstatic to fulfill this request.” The new collection is available in five delightful scents: Olive Sensation, Lavender Relieve, Vitamin Recharge, Jasmine Soothe, and Green Tea Detox. Each scent is made with premium, IFRA-certified fragrances that pair perfectly with VOESH’s best-selling Pedi in a Box Deluxe 4 Step pedicure kits. This allows for a cohesive pampering experience that caters to clients’ preferences. With a transparent ingredient list, dermatologist testing, and U.S. FDA registration, VOESH’s new 28 oz. Vegan Hand & Body Crèmes are the best addition to guarantee clients and technicians feel good about what goes on their skin. For more information about VOESH’s new 28 oz. Vegan Hand & Body Crèmes, please visit voeshpro.com. About VOESH New York: Founded in 2013, VOESH New York has emerged as a premier destination for clean and efficacious body care solutions catering to head-to-toe wellness. Noteworthy products include Pedi in a Box, Mani in a Box, the award-winning Shower & Empower Vitamin C Shower Filter, and Collagen Gloves and Socks. VOESH New York is committed to providing 100% vegan, cruelty-free, and sustainable products because every body deserves better beauty! All VOESH New York products are certified by PETA and registered with the US Mocra, EU CPNP and UK SCPN, maintaining vegan, cruelty-free, and dermatologist-tested standards. VOESH New York proudly excludes all 1,680+ EU-banned ingredients and an additional 400+ potentially harmful ingredients. For more information, visit VOESH New York’s website at Voesh.com or contact press@voesh.com. All VOESH New York products are certified by PETA and registered with the EU CPNP, and UK SCPN. Always vegan, cruelty-free, and dermatologist-tested, VOESH New York proudly excludes all 1,680+ EU-banned ingredients and an additional 400+ potentially harmful ingredients. Contact Details Colleen Mathis +1 917-690-5560 Colleen@absoluterrelations.com Company Website https://voesh.com/

September 06, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

NAVEX Announces 2024 Excellence Awards Finalists

NAVEX Global

NAVEX, a leading provider of integrated risk and compliance management software, announces today the 2024 NAVEX Excellence Awards finalists. Now in its fourth year, the awards celebrate organizations that demonstrate exceptional commitment to corporate governance, risk mitigation, and ethical practices. Each year, the NAVEX Excellence Awards highlight how robust governance, risk and compliance (GRC) programs can strengthen corporate culture and meaningfully impact business outcomes that matter. The 2024 finalists exemplify how effective GRC initiatives can proactively manage and mitigate risks when woven into the organizational fabric. "Congratulations to this year’s nominees and finalists for their outstanding achievements," said NAVEX Chief Customer Officer, Steve Chapman. "We are proud to partner with customers who are dedicated to advancing their GRC efforts. These awards shine a spotlight on some of the most innovative and effective programs in the industry, and we applaud the compliance teams at these companies for their ongoing efforts to build highly ethical, risk-aware organizations." The winners will be honored in several categories, including Ethics & Compliance, Risk Management, and Risk and Compliance Program of the Year. Selected from a highly competitive pool of nominations, this year’s finalists include: As in previous years, the judging panel brings together a mix of NAVEX leaders and seasoned GRC professionals. This year’s esteemed panel features: Barbara Boehler, Senior Director, Program on Corporate Compliance and Ethics, Fordham Law Bill Cameron, Founder and Principal, Cameron Advisory Services Carol Williams, CEO and Enterprise Risk Management Consultant, Strategic Decision Solutions Carrie Penman, Chief Risk and Compliance Officer, NAVEX Kyle Brasseur, Former Editor in Chief, Compliance Week Kyle Martin, Vice President of GRC Solutions, NAVEX Matt Kelly, Editor and CEO, Radical Compliance LLC Stephen Chapman, Chief Customer Officer, NAVEX Vera Cherepanova, Ethics Advocate, Consultant, Author, Studio Etica Award recipients will be announced after to the 2024 NAVEX Next Virtual Conference on October 1. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

September 03, 2024 08:06 AM Eastern Daylight Time

Article thumbnail News Release

PRSA Colorado Chapter Announces Winners of the 2024 Gold Picks Awards

PRSA Colorado

The Colorado Chapter of the Public Relations Society of America (PRSA Colorado) hosted its highly anticipated 2024 Gold Picks Awards Ceremony last night at Stick and Feather in Denver, Colo. The event, which has become a cornerstone of the Colorado public relations community, celebrated the outstanding achievements of professionals and organizations in the field of public relations and corporate communications. Honoring Two Pioneers A highlight of the evening was the presentation of Special Awards, including the Jane Dvorak Mentor of the Year Award and the Sharon Linhart PR Person of the Year Award. These awards were renamed at the event in honor of two trailblazers in the Colorado PR community, recognizing their extraordinary contributions to the industry. The 2024 Special Awards winners are: Joe Fuentes Rookie of the Year: Caroline Campbell, VISIT DENVER Jane Dvorak Mentor of the Year Award: Shawna Seldon McGregor, Maverick Public Relations Media Person of the Year: Greg Avery, Denver Business Journal Business Person of the Year: Doyle Albee, Comprise PR Team of the Year: Gomez Howard Group Ayers Chapter Service Award: Liz Viscardi, APR, LV Events and PR Sharon Linhart PR Person of the Year Award: Merideth Hartung, B Public Relations Rising Stars and Industry Leaders The event also shone a spotlight on the next generation of PR professionals. Members of the Public Relations Student Society of America (PRSSA) from the University of Colorado Boulder and Colorado State University were acknowledged for their contributions to the event and their dedication to the profession. The PRSSA's efforts in fundraising and their anticipated participation in the ICON conference in Anaheim, Calif. this fall were particularly commended. 2024 Gold Picks Award Winners All award winners are listed below under their corresponding category. Gold Picks are the highest-scoring awards based on a specific scoring system but each award is judged individually instead of against the other submittals within that category, meaning multiple organizations can win a Gold Pick within the same category. All awards are judged anonymously by another chapter of PRSA. Gold and Silver Pick Awards: Integrated Communications: Consumer Products: Gold: SchroderHaus – "Justin’s Nuts About Bees" Silver: SchroderHaus – "Justin’s #JustinMyLunch Hunger Relief Program" Government: Gold: CIG Public Relations – "Express Lanes Safety Enforcement" Silver: CIG Public Relations – "CDOT’s Cannabis-Impaired Driving Campaign" Associations/Nonprofits/Educational Institutions: Silver: SchroderHaus – "Fairtrade America’s 'We Are Fairtrade.' Awareness Campaign" Events and Observances - Seven or Fewer Days: Government: Gold: National Disabled Veterans Winter Sports Clinic – "Miracles on a Mountainside" Silver: National Renewable Energy Laboratory – "NREL Welcomes Neighbors Back to Campus During Community Open House" Associations/Nonprofits/Educational Institutions: Gold: Meadows PR and Visit Golden – "Goldens in Golden" Silver: CU Boulder Office of Strategic Relations & Communications – "ScienceWriters2023 at CU Boulder" Silver: Metropolitan State University of Denver – "9News Denver Mayoral Debate hosted by MSU Denver" Content Marketing: Government: Silver: CIG Public Relations – "CDOT Motorcycle Safety campaign" Business to Business: Silver: Graebel Companies with Linhart Public Relations – "Amplifying Thought Leadership and Demonstrating Value through Creative Storytelling" Silver: BOK Financial – "Healthcare Cyberattacks Hurt Providers and Patients Alike" Community Relations: Associations/Nonprofits/Educational Institutions: Silver: JKD & Company and The Church of Jesus Christ of Latter-day Saints – "11th Hour Push - Denver’s Giving Machines" Climate Action and Environmental Sustainability: Silver: SideCar Public Relations – "Seizing Streets for Community Not Cars: ¡Viva! Streets Denver Brings a Global Phenomenon to the Mile High City" Influencer Marketing: Micro-Influencers: Silver: SchroderHaus – "Increasing Reach and Credibility through Influencer Partnerships for Clipper Tea" Organizational Awards: Best Agency - Midsize: Gold: B Public Relations – "From Local to Global: B Public Relations Elevates Hospitality Brands and Experiences" Component Awards: Annual Reports: Gold: Western Resource Advocates – "WRA’s 2022 Impact Report - Building a Better West" Gold: JKD & Company – "Native American Bank - Honoring Community" Social Media: Gold: CU Boulder Office of Strategic Relations & Communications – "CU in 60" Gold: SchroderHaus – "Leveraging Social Media for Awareness and Engagement for Clipper Tea" Branded Content: Gold: BOK Financial – "Healthcare Cyberattacks White Paper" Feature Stories: Gold: Linhart Public Relations with Spire Midstream – "Contributed Content Highlights Need for Natural Gas Storage" Gold: CU Boulder Office of Strategic Relations & Communications – "How Animals Get their Stripes and Spots" Gold: Metropolitan State University of Denver – "Call Me Mister" Newsletters/Magazines: Gold: Metropolitan State University of Denver – "RED Newsfeed" Gold: Western Resource Advocates – "Field Notes" Best Use of Generative AI - Direct Audience Engagement: Gold: CIG Public Relations – "CDOT Impaired Driving Holiday Mug Shot Campaign" Data Insights: Gold: Hensel Phelps Marketing Communications Team & Swing Strategic Communication – "Hensel Phelps 2023 Communications Audit" Influencer Marketing: Gold: Linhart Public Relations with Chocolove – "Sweet Success: Activating Existing Brand Fans on Instagram by Showing the Chocolove" Gold: SchroderHaus – "Justin’s #JustinMyLunch Influencer Marketing" Gold: SchroderHaus – "Earth Month Goes Regenerative for Artisan Tropic" Videos: Silver: Metropolitan State University of Denver – "Art of Dueling" Websites: Gold: Western Resource Advocates – "A New Website for Western Resource Advocates’ Future" Podcasts: Silver: National Renewable Energy Laboratory – "NREL Reaches New Audiences with Launch of Science News Podcast" Media Relations: Gold: JKD & Company and The Church of Jesus Christ of Latter-day Saints – "11th Hour Push - Denver’s Giving Machines" Gold: Linhart Public Relations – "Beef. It’s What’s For Dinner. Combines Bench of Culinary Experts and Creative Media Strategy to Garner Year-Round National Media Coverage" Silver: CU Boulder Office of Strategic Relations & Communications – "Full Triceratops Skeleton Now Calls Boulder Home" Silver: SideCar Public Relations – "¡Viva! Streets Denver Drives Sustainability and Community Engagement Through Car-Free Streets" Silver: Barefoot PR – "Delta Dental of Colorado Foundation Invests in Oral Health Equity" Silver: Elasticity on behalf of Elevate Quantum – "A Mountain of Opportunity" Silver: Root Marketing & PR on behalf of Bubbies Fine Foods – "Making a Big Dill Out of Bubbies" Grand Gold Picks: The Grand Bold Pick is awarded to the "Best of Show" for the campaign with the highest overall score. This years, two organizations took home a Grand Gold Pick: Meadows PR and Visit Golden – "Goldens in Golden" National Disabled Veterans Winter Sports Clinic – "Miracles on a Mountainside" PRSA Colorado congratulates all winners for their exemplary work and contributions to the public relations industry in Colorado. The Public Relations Society of America ( www.prsa.org ) is the nation’s largest association for the professional practice of public relations. The Colorado Chapter ( www.prsacolorado.org ), headquartered in Westminster, is consistently one of the largest chapters in the country. The chapter provides timely and profession-specific educational programs, information and networking opportunities to all of its members, which include professionals at all levels working at corporations, local and national public relations agencies, government offices, universities, nonprofits and independent PR practitioners. Contact Details PRSA Colorado Chapter Alicia Nieva-Woodgate +1 415-515-0866 info@prsacolorado.org Company Website https://prsacolorado.org/

August 29, 2024 04:24 PM Eastern Daylight Time

Article thumbnail News Release

Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data

Global Markets News

Nuvectis Pharma (NASDAQ: NVCT) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation for its lead candidate, NXP800. This designation, specifically for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers, marks a critical step forward in Nuvectis’s mission to address unmet needs in oncology. Orphan Drug Designation: A Strategic Advantage The FDA’s Orphan Drug Designation is awarded to drugs that show promise in treating rare diseases affecting fewer than 200,000 people in the U.S. For Nuvectis, this designation not only validates the potential of NXP800 but also provides several strategic benefits. These include tax credits for clinical trial costs, exemption from certain FDA fees, and potentially seven years of market exclusivity upon approval. NXP800 targets ARID1a-deficient cancers, a subset of ovarian cancers that present significant treatment challenges. The Orphan Drug Designation underscores the importance of this candidate in potentially offering a new, more effective treatment option for patients with this specific genetic mutation. Background and Market Impact This latest achievement builds on Nuvectis Pharma’s earlier successes. Earlier this year, the FDA granted Fast Track Designation to NXP800 for its development in platinum-resistant, ARID1a-mutated ovarian cancer. The Fast Track status, combined with the Orphan Drug Designation, highlights the urgent need for innovative treatments in this space and positions NXP800 as a potential game-changer in oncology. Financial analysts have taken note of Nuvectis’s progress. H.C. Wainwright recently reiterated its buy rating for Nuvectis, setting a price target of $21. This optimistic outlook reflects the market’s confidence in the company’s strategic direction, particularly as it prepares to release key clinical data later this year. Anticipation for Upcoming Results The next few months are expected to be pivotal for Nuvectis Pharma. The company is poised to share updates from its ongoing Phase 1b clinical trial of NXP800, which targets patients with platinum-resistant, ARID1a-mutated ovarian cancer. This trial is being closely watched, as positive results could significantly advance the development of NXP800, bringing it closer to pivotal trials and eventual regulatory approval. Additionally, Nuvectis is also conducting a Phase 1a dose escalation study for NXP900, its second key candidate, which targets YES1/SRC-driven tumors. Updates from this study are expected to provide further insights into the safety and potential efficacy of NXP900. ### Nuvvectis' Full announcment, titled " Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers" was published on August 29th, 2024. ### This article is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. https://justpaste.it/fcm9n/pdf. Global Markets News Network is a commercial digital brand compensated to provide coverage of innovative companies and industries and it is thus subject to conflicts of interest. Contact Details Global Markets News News Coverage ronald@futuremarketsresearch.com

August 29, 2024 08:20 AM Eastern Daylight Time

12345 ... 105